While you can’t teach an old dog new tricks, you may be able to make your pup young again.
A Harvard startup has begun preliminary experiments on beagles and claims it can make animals ‘younger’ by adding new DNA instructions to their bodies.
Continue reading “Startup that wants you to ‘live to 130 in the body of a 22-year-old’” »
And inflammation is one of the three primary ageing processes.
Scientists have discovered a new metabolic process in the body that can switch off inflammation. They have discovered that ‘itaconate’—a molecule derived from glucose—acts as a powerful off-switch for macrophages, which are the cells in the immune system that lie at the heart of many inflammatory diseases including arthritis, inflammatory bowel disease and heart disease.
The scientists, working in the School of Biochemistry and Immunology in the Trinity Biomedical Sciences Institute at Trinity College Dublin, hope their discovery will have relevance for inflammatory and infectious diseases—and that their findings may also help to develop much-needed new drugs to treat people living with these conditions.
Professor of Biochemistry at Trinity, Luke O’Neill, was, along with Dr. Mike Murphy of the University of Cambridge, the joint leader of the work just published in leading international journal Nature. The discoveries were made using both human cells and mice as a model organism.
Continue reading “Scientists discover promising off-switch for inflammation” »
We’ve all dreamed of owning, or at the very least being a passenger of, a flying car. It’s the sci-fi dream that never transpired — until recently, that is. With a growing emphasis of developing flying taxis among several different companies, one wonders if the revolutionary Tesla Motors has plans to join in on this new venture.
Could Elon Musk’s random tweet from late last year be an indicator of Tesla’s interest in flying cars and their joining of this brand new “space race?”
Future wars could be much more fierce with weapons even more powerful than nukes:
The world is progressing in many ways, but tribalism isn’t going away, so new arms races in AI, drones, bio-weapons and space weapons are already under way. Forewarned is forearmed. What sort of weaponry should we expect? I’ve discussed AI and bio approaches before on other blogs, so this one looks just at kinetic weaponry using advanced materials, coupled to EM acceleration systems.
https://carbondevices.com/2017/08/31/using-inverse-rail-guns…ce-launch/ shows a crude illustration of my invention, the inverse rail gun, which inverts the idea of using a slug on a short rail gun and uses the short rail gun to accelerate a long tape instead.
Taking the road less traveled is extremely difficult for self-driving cars. Autonomous vehicles rely on highly visible lane markings, as well as detailed 3D maps in order to navigate their environment safely. Which is why most of the major companies have eschewed testing on unmapped rural roads in favor of suburbs and cities.
Researchers at MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) have developed a new system that allows self-driving cars to drive on roads they’ve never been on before without 3D maps. Called MapLite, the system combines simple GPS data that you’d find on Google Maps with a series of sensors that observe the road conditions.
Continue reading “MIT built a self-driving car that can navigate unmapped country roads” »
The researchers found that when taking the supplement, dilation of subjects’ arteries improved by 42 percent, making their blood vessels, at least by that measure, look like those of someone 15 to 20 years younger.
Excess reactive oxygen species production by mitochondria is a key mechanism of age-related vascular dysfunction. Our laboratory has shown that supplementation with the mitochondrial-targeted antioxidant MitoQ improves vascular endothelial function by reducing mitochondrial reactive oxygen species and ameliorates arterial stiffening in old mice, but the effects in humans are unknown. Here, we sought to translate our preclinical findings to humans and determine the safety and efficacy of MitoQ. Twenty healthy older adults (60–79 years) with impaired endothelial function (brachial artery flow–mediated dilation 6%) underwent 6 weeks of oral supplementation with MitoQ (20 mg/d) or placebo in a randomized, placebo-controlled, double-blind, crossover design study.
